Effect of magnesium sulphate on adriamycin-induced clastogenic and biochemical changes in Swiss albino mice.
Magnesium sulphate (magnesium), an essential anti-oxidant macromineral, was evaluated for its effects on the clastogenic and biochemical changes induced by Adriamycin (ADM) in Swiss albino mice. Male mice were treated orally with different doses (125, 250 and 500 mg/kg body weight/day) of magnesium sulphate for 7 days. Some of these mice were injected intraperitoneally with ADM (8 mg/kg body weight). Multiple sampling (12, 24 and 48 h) were carried out after the last treatment in different experiments. The animals were sacrificed under ether anaesthesia. The concentrations of magnesium were determined in plasma and liver tissue. Femoral marrow cells were collected and screened for the frequency of micronuclei and the ratio of polychromatic erythrocytes to normochromatic erythrocytes. Furthermore the proteins, nucleic acids, malondialdehyde (MDA) and non-protein sulphydryl (NPSH) levels were estimated in hepatic cells. The magnesium sulphate treatment did not affect the magnesium concentrations in plasma and liver tissue. The treatment also failed to cause any significant clastogenic, cytotoxic and biochemical changes. Pretreatment with magnesium sulphate showed no alterations in plasma and hepatic tissue levels of magnesium. Nevertheless the pretreatment was found to inhibit the ADM-induced micronuclei without any alteration in its therapeutic efficacy. The proteins, DNA, RNA and MDA levels in the hepatic cells of these animals were increased and the NPSH concentrations were reduced. The anticlastogenic nature of magnesium sulphate appears to be related to its pretreatment which might have averted the free-radical-mediated pathogenesis induced by ADM.
Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
O A
OA
Al-Shabanah
D000277:Adjuvants, Pharmaceutic; D000818:Animals; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004247:DNA / Q000378:metabolism; D004317:Doxorubicin / Q000633:toxicity*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008278:Magnesium Sulfate / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D051379:Mice; D048629:Micronuclei, Chromosome-Defective / Q000187:drug effects; D011506:Proteins / Q000378:metabolism; D012313:RNA / Q000378:metabolism; D012307:Risk Factors; D013438:Sulfhydryl Compounds / Q000378:metabolism
D000277:Adjuvants, Pharmaceutic; D011506:Proteins; D013438:Sulfhydryl Compounds; D012313:RNA; D008278:Magnesium Sulfate; D004317:Doxorubicin; D004247:DNA